Vaccinex reports Q3 revenue $404,000, consensus 30,000
"The highlight of our activities during the third quarter was the positive interim data from our CLASSICAL-Lung study that we presented in September at the Fifth International Cancer lmmunotherapy Conference in Paris, France, and which we recently updated at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting," commented Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex. "We are very pleased that patients appear to be experiencing durable clinical benefit from the combination of pepinemab plus avelumab, in many cases even after progression on prior immune checkpoint inhibitor therapy. We believe the many patients who do not respond or who relapse following single agent immunotherapy represent an important unmet need for NSCLC, and our data suggest that the combination treatment may overcome inherent or acquired resistance to anti-PD-1/PD-L1 therapy. In parallel with our CLASSICAL-Lung study, we continue to advance our SIGNAL trial in Huntington's disease, our most advanced indication, and anticipate submitting for publication our data from Cohort A before the end of the year. We continue to believe these trials offer multiple opportunities to demonstrate the broad utility of pepinemab in treating serious diseases," Dr. Zauderer concluded.